UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
TipRanks on MSN
ECD Automotive Design’s $300M Stock Sale Approval
ECD Automotive Design ( ($ECDA) ) has provided an update. On November 3, 2025, ECD Automotive Design, Inc.’s registration statement on Form S-1 ...
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.
The FDA has announced new rules for the approval of biosimilar drug products that could reduce 5- to 8-year timelines by half.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback